Ipatasertib: An Investigational Targeted Cancer Therapy

Ipatasertib is an oral drug designed to block a protein called AKT, which many cancers hijack to fuel their growth and resist treatment. Developed by Genentech/Roche and sometimes referred to by its research code GDC-0068, ipatasertib has been tested across several tumor types, most extensively in metastatic prostate cancer and triple-negative breast cancer. Despite encouraging results in early-stage trials, the drug has so far failed to deliver consistent survival benefits in large phase 3 studies, and it remains investigational with no regulatory approval to date.

What AKT Does in Cancer and Why Blocking It Matters

AKT is a signaling protein that normally helps cells survive and grow. In healthy tissue that process is tightly controlled, but in many cancers AKT becomes overactive, sending constant “stay alive” signals that let tumor cells dodge the normal mechanisms of cell death. Overactive AKT has been linked to poor outcomes and resistance to both hormone therapy and chemotherapy in breast cancer, among other tumor types.¹ Ipatasertib works by physically fitting into AKT’s active site, the pocket where the protein normally binds to ATP to carry out its functions, and shutting it down. Several other drugs in its class do the same thing, including capivasertib, which has since gained approval for certain breast cancers.²

Which Tumors Are Most Likely to Respond

Not every cancer depends on AKT equally, so researchers have looked for molecular markers that predict which patients might benefit most. Two alterations stand out: loss of a tumor suppressor gene called PTEN and mutations in a gene called PIK3CA. Both changes ramp up AKT signaling, making those tumors more reliant on the pathway ipatasertib blocks. In lab experiments, cancer cell lines carrying either of these alterations were substantially more sensitive to ipatasertib than cell lines without them.³

This idea, that PTEN loss or PIK3CA mutations should identify the patients who benefit, became the central hypothesis in nearly every major ipatasertib trial. In prostate cancer studies, patients were stratified by PTEN status measured through a staining technique on tumor tissue. In breast cancer studies, researchers looked at PIK3CA/AKT1/PTEN alterations using both tissue staining and genomic sequencing.⁴ The question of how to test for these alterations is not trivial; different methods sometimes yield different patient selections, and as we will see, that has complicated the interpretation of trial results.

The Prostate Cancer Story

Prostate cancer, specifically metastatic castration-resistant prostate cancer (mCRPC), became the highest-profile testing ground for ipatasertib. The rationale was straightforward: PTEN loss is common in aggressive prostate cancers and is associated with worse outcomes, and combining an AKT blocker with abiraterone (a drug that suppresses androgen production) could hit the cancer from two angles at once.

An early phase 2 trial provided reason for optimism. Among patients whose tumors had lost PTEN, ipatasertib at the full dose of 400 mg slowed disease progression compared to placebo, with a hazard ratio of 0.39, meaning the risk of progression dropped by roughly 60 percent in that subgroup.⁵ That result prompted the large phase 3 trial known as IPATential150, which enrolled over 1,100 men.

IPATential150 did show a statistically significant improvement in radiographic progression-free survival among PTEN-loss patients: roughly 18.5 months with ipatasertib versus 16.5 months with placebo.⁶ But the two-month gain was modest, and when researchers followed patients longer to see whether the drug helped them live longer overall, the answer was no. At a median follow-up of nearly 34 months, overall survival was not improved in either the PTEN-loss group or the full study population.⁷

One intriguing finding from IPATential150 emerged when researchers went beyond tissue staining and used genomic sequencing to identify PTEN alterations. A smaller group of patients with genomic PTEN loss or with combined PIK3CA/AKT1/PTEN alterations showed hints of a stronger benefit, with hazard ratios around 0.70 to 0.76 for overall survival, though these results were exploratory and not statistically definitive.⁷ Separately, molecular subtyping of tumors found that patients whose cancers had high androgen-receptor signaling and cell-cycle activity saw a more meaningful delay in progression when given ipatasertib.⁸ These hints suggest that the biomarker strategy used in the trial, standard tissue staining for PTEN, may not have been precise enough to identify the patients who truly benefit.

Triple-Negative Breast Cancer Trials

Triple-negative breast cancer (TNBC) has few targeted treatment options, which made the AKT pathway an attractive target. The phase 2 LOTUS trial was the first to test ipatasertib with paclitaxel chemotherapy in first-line metastatic TNBC, and it showed promising results: median progression-free survival was about 6.2 months with ipatasertib versus 4.9 months with placebo.⁹ Researchers noted at the time that these were the first results supporting AKT-targeted therapy for TNBC.

That enthusiasm, however, did not survive the larger follow-up. The phase 3 IPATunity130 trial specifically enrolled patients whose tumors had PIK3CA/AKT1/PTEN alterations, the very population predicted to benefit most. Yet adding ipatasertib to paclitaxel provided no improvement whatsoever. Median progression-free survival was 7.4 months with ipatasertib and 6.1 months with placebo, a difference that was not statistically or clinically meaningful. Overall survival was similarly unchanged, at roughly 24 months in both groups.¹⁰ This was a significant setback, and it echoed the pattern seen in prostate cancer: encouraging phase 2 signals that faded in larger, more rigorous trials.

One silver lining from IPATunity130 was that quality-of-life scores remained stable in both arms. Patients who received ipatasertib did not experience a clinically meaningful drop in their self-reported well-being compared to those on placebo, suggesting the drug’s side effects, while real, did not substantially erode daily functioning during the treatment period.¹¹

Attempts in Other Cancer Types

Ipatasertib has been tested beyond prostate and breast cancers, though the results have generally not supported further development. A randomized phase 2 trial combined ipatasertib with standard chemotherapy (mFOLFOX6) in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer. Among 153 patients, ipatasertib actually performed slightly worse numerically than placebo, with median progression-free survival of 6.6 months versus 7.5 months, and no benefit was seen even in subgroups selected by PTEN or PI3K/AKT pathway status.¹²

A basket trial run through the U.S. National Cancer Institute’s MATCH program (EAY131 Subprotocol Z1K) tested ipatasertib in patients whose tumors carried specific AKT mutations, regardless of tumor type. While detailed efficacy data from that trial is still being assessed, the safety data confirmed the drug’s known side-effect profile across a broader range of cancers.¹³ Smaller studies have also examined combinations with immunotherapy drugs, such as the checkpoint inhibitor atezolizumab, in TNBC.¹⁴

Side Effects

Ipatasertib’s side-effect profile is consistent across trials and is closely tied to blocking AKT, which plays a role in glucose regulation and gut function. In the first-in-human phase 1 trial, the most frequently reported side effects at grade 2 or higher were diarrhea (about 35 percent of patients), nausea (27 percent), fatigue (25 percent), and elevated blood sugar (10 percent). Serious side effects were mainly seen at higher doses (600 mg and above), and no treatment-related deaths occurred.³ The NCI-MATCH trial data echoed this pattern, with diarrhea, nausea, and hyperglycemia again topping the list.¹³

The hyperglycemia risk deserves particular attention. Because AKT is a key player in insulin signaling, blocking it predictably raises blood sugar levels. For patients who already have diabetes or prediabetes, this is a side effect that requires careful monitoring. Diarrhea, meanwhile, is manageable in most patients with standard anti-diarrheal medications, but at higher doses it has been a reason for dose reductions.

How the Body Handles Ipatasertib

Ipatasertib is taken as a daily pill, but only about a third of the drug reaches the bloodstream. Its absolute bioavailability is around 34 percent, meaning most of the oral dose is lost before it can get to work. The drug is cleared primarily by the liver, where an enzyme called CYP3A breaks it down, and its half-life is roughly 27 hours, long enough to support once-daily dosing. Most of the drug leaves the body through stool (about 69 percent of radioactive-labeled dose) and urine (about 19 percent), overwhelmingly as metabolized products rather than unchanged drug.¹⁵

The reliance on CYP3A for metabolism has practical implications. Strong inhibitors of that enzyme, which include certain antifungal drugs and grapefruit juice, could raise ipatasertib levels in the blood, potentially increasing side effects. Conversely, drugs that rev up CYP3A activity, such as some anti-seizure medications, could lower ipatasertib’s effectiveness. Pharmacokinetic modeling has also revealed that ipatasertib’s bioavailability and the formation of its main metabolite increase with repeated daily dosing, meaning drug exposure accumulates beyond what simple dose-stacking would predict.¹⁶

Why Tumors Become Resistant

Even when ipatasertib initially slows a cancer, tumors often find workarounds. Recent research in prostate cancer models has revealed that the earliest and most common escape route involves restoring activity of a protein complex called mTOR, which normally sits downstream of AKT. When AKT is blocked, you would expect mTOR to quiet down too, but resistant tumors reactivate it through an unexpected side door: the nutrient-sensing pathway. By losing components of molecular complexes called GATOR and KICSTOR, or by ramping up amino acid recycling within cells, tumors restore mTOR signaling independently of AKT.¹⁷

A separate mechanism involves autophagy, the cell’s internal recycling process. Studies in triple-negative breast cancer models found that ipatasertib treatment cranks up autophagy signaling, essentially allowing cancer cells to eat their own damaged parts for fuel and survive. In lab experiments, adding chloroquine, a drug that blocks autophagy, restored the sensitivity of resistant TNBC cells to both ipatasertib and paclitaxel chemotherapy.¹⁸ Whether that finding will translate into better outcomes for patients remains to be tested in clinical trials, but it points to a potential strategy for overcoming resistance.

Limited Reach Into the Brain

Brain metastases are a serious concern in several cancers where ipatasertib has been studied, and the drug’s ability to cross the blood-brain barrier is limited. Preclinical testing found that ipatasertib achieves a brain-to-plasma ratio of about 0.20, meaning brain concentrations are roughly a fifth of blood levels.¹⁹ Part of the reason is that ipatasertib appears to be a substrate for efflux pumps, proteins that actively push the drug back out of cells. In permeability assays, ipatasertib showed a very high efflux ratio, suggesting these pumps work hard to keep it out of the brain.²⁰

Interestingly, the same brain metastasis study in mice showed that ipatasertib could slow tumor growth and extend survival in a specific breast cancer model with PIK3CA mutations, despite the limited penetration.²⁰ However, a more recent study in pediatric-type diffuse high-grade gliomas found no significant survival benefit from ipatasertib despite a similar brain-to-plasma ratio, suggesting that partial brain penetration is not always enough.¹⁹ For patients with brain involvement, this remains an important limitation.

The Biomarker Problem

Running through all of ipatasertib’s clinical results is a recurring theme: the biomarker strategy has not worked as well as hoped. The logic was sound: find tumors driven by AKT pathway activation, give those patients ipatasertib, and expect a bigger benefit. But the tools used to identify those tumors, primarily tissue staining for PTEN loss, may be too blunt. In the prostate cancer trial, tissue staining identified about 47 percent of patients as PTEN-loss, a large group that likely included many tumors that were not truly dependent on the AKT pathway for survival.⁶ When more precise genomic sequencing was used instead, the subgroup that appeared to benefit shrank considerably but showed stronger signals of treatment effect.⁷

This gap between the biomarker prediction and the clinical reality is a problem shared by many targeted therapies. Finding a pathway alteration in a tumor does not always mean the tumor depends on that pathway to grow. Cancers are complex ecosystems with redundant survival circuits, and the resistance mechanisms described above show how quickly tumors can reroute around a blocked pathway. For ipatasertib, the lesson may be that the right patient population exists but has not yet been reliably identified with standard clinical tests.

How Ipatasertib Compares to Capivasertib

Ipatasertib is not the only AKT inhibitor to have been tested in large trials. Capivasertib, developed by AstraZeneca, targets the same protein using a similar mechanism. In 2023, capivasertib became the first AKT inhibitor to gain regulatory approval when it was cleared for use in combination with fulvestrant for certain advanced hormone receptor-positive breast cancers with PIK3CA, AKT1, or PTEN alterations. That approval was based on results from the CAPItello-291 trial, which showed a significant progression-free survival benefit in the biomarker-selected population.

The divergent fates of these two drugs illustrate how much trial design, combination partner, and patient selection matter in targeted therapy. Capivasertib was tested in a hormone receptor-positive population with a different combination partner and a different biomarker enrichment strategy. Ipatasertib’s biggest trials were in TNBC and prostate cancer, tumor types that may pose different biological challenges for AKT inhibition. The failure of one AKT inhibitor in a specific tumor type does not necessarily predict failure for all AKT inhibitors in all settings, and the success of capivasertib confirms that the target itself remains valid.

Autophagy as a Potential Combination Target

The finding that autophagy drives resistance to ipatasertib has opened an intriguing line of investigation. In breast cancer models, chloroquine, a decades-old antimalarial drug that happens to block autophagy, restored the effectiveness of both ipatasertib and related PI3K pathway inhibitors. When combined with paclitaxel, the triple combination of chloroquine, ipatasertib, and chemotherapy worked better than any pairing in both cell cultures and mouse models.¹⁸ Chloroquine is inexpensive, widely available, and has a well-understood safety profile from decades of use in malaria treatment, making it a practical candidate for combination studies if the preclinical findings hold up in patients. Several early-phase clinical trials across different cancer types are now exploring autophagy inhibition as a way to extend the usefulness of pathway-targeted drugs.